Shinji Tsukamoto, Costantino Errani, Tessa Balach, Tomas Zamora, Eduardo Ortiz-Cruz, Raja Bhaskara Rajasekaran, Raymond Yau, Tao Ji, Israel Pérez-Muñoz, Francisco Linares, Andrea Angelini, Pietro Ruggieri, Joseph Benevenia, Andreas F Mavrogenis
{"title":"What's new on giant cell tumor of bone.","authors":"Shinji Tsukamoto, Costantino Errani, Tessa Balach, Tomas Zamora, Eduardo Ortiz-Cruz, Raja Bhaskara Rajasekaran, Raymond Yau, Tao Ji, Israel Pérez-Muñoz, Francisco Linares, Andrea Angelini, Pietro Ruggieri, Joseph Benevenia, Andreas F Mavrogenis","doi":"10.1051/sicotj/2025063","DOIUrl":null,"url":null,"abstract":"<p><p>When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce local recurrence. We present a review of the literature reporting favorable results of radiofrequency ablation alone in locally recurrent small GCTB. New filling materials are also being developed to prevent non-oncological complications such as arthrosis and fractures. Routine measurement of tartrate-resistant acid phosphatase 5b in serum may be helpful in detecting early instances of local recurrence. For unresectable or metastatic GCTB, there is an urgent need for a new drug that is as effective as denosumab, avoids side effects, and can be administered to pregnant women.</p>","PeriodicalId":46378,"journal":{"name":"SICOT-J","volume":"12 ","pages":"2"},"PeriodicalIF":2.3000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12825416/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SICOT-J","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1051/sicotj/2025063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce local recurrence. We present a review of the literature reporting favorable results of radiofrequency ablation alone in locally recurrent small GCTB. New filling materials are also being developed to prevent non-oncological complications such as arthrosis and fractures. Routine measurement of tartrate-resistant acid phosphatase 5b in serum may be helpful in detecting early instances of local recurrence. For unresectable or metastatic GCTB, there is an urgent need for a new drug that is as effective as denosumab, avoids side effects, and can be administered to pregnant women.